Corbus Pharmaceuticals Holdings, Inc. (CRBP) stock
CRBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$3.01−0.37 (-10.81%)
Close on Nov 17, 2026Market cap $58.22MP/E –Yield –
Corbus Pharmaceuticals ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Corbus Pharmaceuticals's ebitda for the twelve months ending Jun 30, 2026 was -$106.68M. For fiscal 2025 it was -$85.08M. The highest annual figure on record is -$8.81M in fiscal 2015.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$85.08M | – |
| FY2024 | Dec 31, 2024 | -$48.13M | – |
| FY2023 | Dec 31, 2023 | -$44.44M | – |
| FY2022 | Dec 31, 2022 | -$39.07M | – |
| FY2021 | Dec 31, 2021 | -$54.99M | – |
| FY2020 | Dec 31, 2020 | -$121.69M | – |
| FY2019 | Dec 31, 2019 | -$76.37M | – |
| FY2018 | Dec 31, 2018 | -$56.25M | – |
| FY2017 | Dec 31, 2017 | -$32.31M | – |
| FY2016 | Dec 31, 2016 | -$19.90M | – |
| FY2015 | Dec 31, 2015 | -$8.81M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$36.14M | – |
| Q1 FY2026 | Mar 31, 2026 | -$24.26M | – |
| Q4 FY2025 | Dec 31, 2025 | -$21.92M | – |
| Q3 FY2025 | Sep 30, 2025 | -$24.37M | – |
| Q2 FY2025 | Jun 30, 2025 | -$19.10M | – |
| Q1 FY2025 | Mar 31, 2025 | -$19.69M | – |
| Q4 FY2024 | Dec 31, 2024 | -$12.47M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.35M | – |
| Q2 FY2024 | Jun 30, 2024 | -$10.84M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.47M | – |
| Q4 FY2023 | Dec 31, 2023 | -$9.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.34M | – |
| Q2 FY2023 | Jun 30, 2023 | -$8.03M | – |
| Q1 FY2023 | Mar 31, 2023 | -$17.12M | – |
| Q4 FY2022 | Dec 31, 2022 | -$10.61M | – |
| Q3 FY2022 | Sep 30, 2022 | -$7.99M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.15M | – |
| Q1 FY2022 | Mar 31, 2022 | -$8.32M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.79M | – |
| Q3 FY2021 | Sep 30, 2021 | -$13.62M | – |
| Q2 FY2021 | Jun 30, 2021 | -$16.44M | – |
| Q1 FY2021 | Mar 31, 2021 | -$15.14M | – |
| Q4 FY2020 | Dec 31, 2020 | -$20.53M | – |
| Q3 FY2020 | Sep 30, 2020 | -$33.77M | – |
| Q2 FY2020 | Jun 30, 2020 | -$37.82M | -2132.2% |
| Q1 FY2020 | Mar 31, 2020 | -$29.57M | – |
| Q4 FY2019 | Dec 31, 2019 | -$26.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$24.94M | – |
| Q2 FY2019 | Jun 30, 2019 | $1.86M | – |
| Q1 FY2019 | Mar 31, 2019 | -$26.37M | – |
| Q4 FY2018 | Dec 31, 2018 | -$17.44M | – |
| Q3 FY2018 | Sep 30, 2018 | -$14.77M | – |
| Q2 FY2018 | Jun 30, 2018 | -$12.27M | – |
| Q1 FY2018 | Mar 31, 2018 | -$11.78M | – |
| Q4 FY2017 | Dec 31, 2017 | -$10.80M | – |
| Q3 FY2017 | Sep 30, 2017 | -$6.83M | – |
| Q2 FY2017 | Jun 30, 2017 | -$7.26M | – |
| Q1 FY2017 | Mar 31, 2017 | -$7.42M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.54M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.31M | – |
See a number that looks wrong?